These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. Thomas SE; Barenbrug L; Hannink G; Seyger MMB; de Jong EMGJ; van den Reek JMPA Drugs; 2024 May; 84(5):565-578. PubMed ID: 38630365 [TBL] [Abstract][Full Text] [Related]
25. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593 [TBL] [Abstract][Full Text] [Related]
28. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. Tausend W; Downing C; Tyring S J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703 [TBL] [Abstract][Full Text] [Related]
29. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data. Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316 [TBL] [Abstract][Full Text] [Related]
30. Anti IL-17 in psoriasis. Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358 [No Abstract] [Full Text] [Related]
31. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757 [TBL] [Abstract][Full Text] [Related]
32. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Dong J; Goldenberg G Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618 [TBL] [Abstract][Full Text] [Related]
33. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis. Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174 [TBL] [Abstract][Full Text] [Related]
34. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Mease PJ Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143 [TBL] [Abstract][Full Text] [Related]
36. Anti-IL-17 phase II data for psoriasis: A review. Brown G; Malakouti M; Wang E; Koo JY; Levin E J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO; J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163 [TBL] [Abstract][Full Text] [Related]